Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.53 |
| ▸ | AURKA | O14965 | 11/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | CFTR | P13569 | 2/20 | 0.45 |
| ▸ | BRS3 | P32247 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186377 | 0.95 | IGF1R (0.49) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL10149993 | 0.95 | AURKA (0.51) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL10186371 | 0.88 | CFTR (0.51) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL12430748 | 0.86 | IGF1R (0.54) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL10186617 | 0.84 | CFTR (0.50) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL12430781 | 0.82 | AURKA (0.47) | IGF1RAURKAAURKBGSK3BGSK3A | |
| SCHEMBL12430747 | 0.80 | IGF1R (0.49) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL801533 | 0.80 | IGF1R (0.71) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL801536 | 0.79 | IGF1R (0.70) | IGF1RAURKAAURKBSRCGSK3B | |
| SCHEMBL12430751 | 0.79 | AURKA (0.53) | IGF1RAURKAAURKBSRCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | KCNQ1, KCNN2, KCNH3 | IGF1R 4782/4885AURKA 2842/4885AURKB 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.